Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Therapeutic areas › Renal

Renal (22 companies · 15 conditions)

Conditions

Lupus Nephritis 11 Rare Immunoglobulin A Nephropathy 7 Rare Focal Segmental Glomerulosclerosis 4 Rare Membranous Nephropathy 4 Rare Chronic Kidney Disease 2 Hyperphosphatemia 2 Minimal Change Disease 2 Rare Polycystic Kidney Disease 2 Rare Acute Kidney Injury 1 Alport Syndrome 1 Rare Atypical Hemolytic Uremic Syndrome 1 Rare C3 Glomerulopathy 1 Rare Cystinuria 1 Rare Delayed Graft Function 1 Diabetes Insipidus 1 Rare

Companies

Ticker Company Therapeutic areas In Renal Lead stage Programs
ACET Adicet Bio ImmunologyNeurology+2 Rare 1 Phase 1 8
AKBA Akebia Therapeutics HematologyOphthalmology+2 Rare 7 Approved 10
ANNX Annexon HematologyNeurology+2 Rare 1 Phase 3 6
ARDX Ardelyx GI/HepatologyRenal 1 Approved 4
ARTV Artiva Biotherapeutics DermatologyImmunology+2 Rare 1 Phase 2 14
AUTL Autolus Therapeutics HematologyImmunology+3 Rare 1 Approved 12
CABA Cabaletta Bio DermatologyImmunology+2 Rare 1 Phase 1 8
IPSC Century Therapeutics ImmunologyMetabolic+1 Rare 2 Phase 1 9
CLYM Climb Bio HematologyImmunology+1 Rare 3 Phase 2 7
CGEM Cullinan Therapeutics HematologyImmunology+2 Rare 1 NDA Submitted 10
ELOX Eloxx Pharmaceuticals DermatologyRenal Rare 2 Phase 2 4
ETON Eton Pharmaceuticals GI/HepatologyInfectious Disease+2 Rare 1 Approved 14
JBIO Jade Biosciences ImmunologyRenal Rare 1 Phase 2 4
KYTX Kyverna Therapeutics ImmunologyNeurology+1 Rare 1 NDA Submitted 7
NKTX Nkarta ImmunologyNeurology+1 Rare 2 Phase 1 8
NVCT Nuvectis Pharma HematologyOncology+1 Rare 2 Phase 3 8
PCSA Processa Pharmaceuticals GI/HepatologyImmunology+2 Rare 2 Phase 2 7
SCYX Scynexis Infectious DiseaseRenal Rare 1 Approved 5
TVTX Travere Therapeutics MetabolicRenal Rare 6 Approved 7
UNCY Unicycive Therapeutics Renal 2 NDA Submitted 2
VERA Vera Therapeutics Infectious DiseaseRenal Rare 4 Approved 6
XNCR Xencor HematologyImmunology+4 Rare 1 Approved 36